The importance of pharmacoepidemiology in pregnancy-implications for safety

被引:24
作者
Benevent, Justine [1 ]
Montastruc, Francois [1 ]
Damase-Michel, Christine [1 ]
机构
[1] Univ Toulouse III, Fac Med, CRPV Midi Pyrenees, CHU Toulouse,UMR INSERM 1027,CIC 1436, Toulouse, France
关键词
Electronic database; medication; pharmacoepidemiology; pregnancy; teratogen; TERATOLOGY INFORMATION-SERVICES; IN-UTERO EXPOSURE; CONGENITAL-MALFORMATIONS; DRUG; RISK; PRESCRIPTION; EFEMERIS; COHORT; DATABASE; DEFECTS;
D O I
10.1080/14740338.2017.1363177
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Prescription of medications to pregnant women is usually a challenge as the drug benefit has to be considered regarding its potential adverse effects. As medication use is common in pregnant women, by chance or necessity, it gives the opportunity to evaluate the consequences of prenatal drug exposure in real life through pharmacoepidemiologic studies. Area covered: Data sources are numerous. Some of them have been created for the particular purpose of assessing medications during pregnancy. Augmented databases enable the study of delayed effects in late childhood and provide information on potential confounders. Each data source exhibits strengths and weaknesses. Several designs can be used to assess the safety of medications during pregnancy. Innovative designs have been developed in order to bypass major limits of classical methods. Expert opinion: An efficient system could follow up each pregnant woman, who had taken a medication, and consider her as a precious information for the knowledge of drug potential adverse actions against the child, who must be followed up to identify long term-effects. The diversity of data sources and approaches of pharmacoepidemiologic studies, the implementation of international networks as well as the improvement of adverse signal detection are the keystones of such an evaluation.
引用
收藏
页码:1181 / 1190
页数:10
相关论文
共 54 条
[21]   The Nordic Countries as a Cohort for Pharmacoepidemiological Research [J].
Furu, Kari ;
Wettermark, Bjorn ;
Andersen, Morten ;
Martikainen, Jaana E. ;
Almarsdottir, Anna Birna ;
Sorensen, Henrik Toft .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2010, 106 (02) :86-94
[22]   Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study [J].
Graner, Sophie ;
Svensson, Tobias ;
Beau, Anna-Belle ;
Damase-Michel, Christine ;
Engeland, Anders ;
Furu, Kari ;
Hviid, Anders ;
Haberg, Siri Eldevik ;
Molgaard-Nielsen, Ditte ;
Pasternak, Bjrn ;
Kieler, Helle .
BMJ-BRITISH MEDICAL JOURNAL, 2017, 356
[23]   The Implications of Unintended Pregnancies for Mental Health in Later Life [J].
Herd, Pamela ;
Higgins, Jenny ;
Sicinski, Kamil ;
Merkurieva, Irina .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2016, 106 (03) :421-429
[24]   Case-crossover and case-time-control designs in birth defects epidemiology [J].
Hernández-Díaz, S ;
Hernán, MA ;
Meyer, K ;
Werler, MM ;
Mitchell, AA .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2003, 158 (04) :385-391
[25]   Interest of the trajectory method for the evaluation of outcomes after in utero drug exposure: example of anxiolytics and hypnotics [J].
Hurault-Delarue, Caroline ;
Chouquet, Cecile ;
Savy, Nicolas ;
Lacroix, Isabelle ;
Beau, Anna-Belle ;
Montastruc, Jean-Louis ;
Damase-Michel, Christine .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (05) :561-569
[26]   How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women? [J].
Hurault-Delarue, Caroline ;
Chouquet, Cecile ;
Savy, Nicolas ;
Lacroix, Isabelle ;
Beau, Anna-Belle ;
Montastruc, Jean-Louis ;
Damase-Michel, Christine .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 (07) :770-777
[27]   Prescription of drugs during pregnancy in France [J].
Lacroix, I ;
Damase-Michel, C ;
Lapeyre-Mestre, M ;
Montastruc, J .
LANCET, 2000, 356 (9243) :1735-1736
[28]   Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database [J].
Lacroix, I. ;
Hurault, C. ;
Sarramon, M. F. ;
Guitard, C. ;
Berrebi, A. ;
Grau, M. ;
Albouy-Cossard, C. ;
Bourrel, R. ;
Elefant, E. ;
Montastruc, J. L. ;
Damase-Michel, C. .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (08) :839-846
[29]   In Utero Exposure to Venlafaxine, a Serotonin-Norepinephrine Reuptake Inhibitor, Increases Cardiac Anomalies and Alters Placental and Heart Serotonin Signaling in the Rat [J].
Laurent, Laetitia ;
Huang, Chunwei ;
Ernest, Sheila R. ;
Berard, Anick ;
Vaillancourt, Cathy ;
Hales, Barbara F. .
BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2016, 106 (12) :1044-1055
[30]  
Leen-Mitchell M, 2000, TERATOLOGY, V61, P314, DOI 10.1002/(SICI)1096-9926(200004)61:4<314::AID-TERA11>3.0.CO